Home/Indications/Skin and Skin Structure Infections

Skin and Skin Structure Infections

0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Skin and Skin Structure Infections has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Skin and Skin Structure Infections Treatments by Mechanism

Top 1 mechanisms across 1 industry trials with a known mechanism of action.

See full pipeline →

Lipopeptide Antibacterial

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Skin and Skin Structure Infections Clinical Pipeline by Phase

20 industry-sponsored trials across 14 sponsors

Showing 3 of 3 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Usual Care	—	COMPLETED	2019-03-29	NCT02961764
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Daptomycin	Lipopeptide Antibacterial [EPC]	COMPLETED	2012-09-01	NCT01419184
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Vancomycin	—	TERMINATED	2012-06-12	NCT01104662

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Dalbavancin	—	COMPLETED	2024-01-01	NCT02814916
Merck	Tedizolid phosphate	—	COMPLETED	2023-07-06	NCT03176134
Basilea Pharmaceutica	ceftobiprole medocaril	—	COMPLETED	2019-04-22	NCT03137173
Wockhardt	Oral Levonadifloxacin/Linezolid Tablet	—	COMPLETED	2018-09-25	NCT03405064
Arrevus Inc.	sodium fusidate	—	COMPLETED	2016-11	NCT02570490
Stiefel, a GSK Company	Retpamulin Ointment, 1%	—	COMPLETED	2010-07	NCT00852540
GSK	Retapamulin Ointment, 1%	—	COMPLETED	2009-10	NCT00684177

Showing 6 of 6 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Lytix Biopharma AS	LTX-109	—	COMPLETED	2011-02	NCT01223222
GSK	GSK1322322	—	COMPLETED	2011-01-18	NCT01209078
Furiex Pharmaceuticals, Inc	JNJ-32729463	—	COMPLETED	2010-12	NCT01128530
Novexel Inc	NXL103	—	COMPLETED	2010-03	NCT00949130
Protez Pharmaceuticals, Inc.	PZ-601	—	COMPLETED	2009-02	NCT00671580
Melinta Therapeutics, Inc.	delafloxacin	—	COMPLETED	2008-10	NCT00719810

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
GSK	Retapamulin Microdialysis	—	COMPLETED	2014-05-27	NCT01812382
GSK	Isotretinoin 40 mg	—	COMPLETED	2011-09-23	NCT01863615
GSK	Minocycline 100mg	—	COMPLETED	2011-06-25	NCT01755611
Pfizer	SA3Ag vaccine	—	COMPLETED	2011-01	NCT01018641

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Skin and Skin Structure Infections

Beta-lactamase-producing bacteria (3) β-lactamase–negative bacteria (1)

Novel Skin and Skin Structure Infections Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (13 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

CEFAZOLIN IN DEXTROSE

Baxter

T5 2015

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

T5 2010